Overview Dividends

(HALO) Halozyme Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US40637H1095

Enzyme, Cancer, Immunodeficiency, Autoimmune, Multiple Sclerosis

HALO EPS (Earnings per Share)

EPS Growth (3Y CAGR): 30.54%
EPS Trend (3Y Correlation): 88.4%

HALO Revenue

Revenue Growth (3Y CAGR): 17.51%
Revenue Trend (3Y Correlation): 84.1%

Description: HALO Halozyme Therapeutics November 05, 2025

Halozyme Therapeutics (NASDAQ:HALO) is a San-Diego-based biopharma that commercializes its patented recombinant human hyaluronidase (rHuPH20) platform, which facilitates sub-cutaneous delivery of large-molecule biologics and small-molecule drugs. The company’s current marketed portfolio includes Hylenex (rHuPH20-enhanced SC injections), XYOSTED (testosterone replacement), and a suite of partner-backed products such as Herceptin Hylecta, Phesgo, Mabthera SC, HYQVIA, Ocrevus, DARZALEX, and OTREXUP, among others.

Key quantitative points (as of the most recent Q2 2024 filing) – Revenue grew 22 % YoY to $215 million, driven primarily by expanding SC formulations with Roche and AbbVie; cash and short-term investments stood at $460 million, providing ~18 months of runway at current burn; and the rHuPH20 platform is estimated to address a $12 billion global market for SC biologics, a sector that is expanding at ~8 % CAGR as patients and payers favor outpatient administration. Halozyme’s partnership pipeline (e.g., upcoming SC versions of Ocrevus and DARZALEX) represents a material upside catalyst, but execution risk remains high because regulatory timelines and commercial uptake are uncertain.

If you want a data-rich, model-ready view of Halozyme’s valuation assumptions and scenario analysis, the ValueRay platform offers a transparent dashboard that can help you test those drivers further.

HALO Stock Overview

Market Cap in USD	7,625m
Sub-Industry	Biotechnology
IPO / Inception	2004-03-16

HALO Stock Ratings

Growth Rating	51.6%
Fundamental	86.3%
Dividend Rating	-
Return 12m vs S&P 500	-2.19%
Analyst Rating	3.63 of 5

HALO Dividends

Currently no dividends paid

HALO Growth Ratios

Growth Correlation 3m	-27.1%
Growth Correlation 12m	67.1%
Growth Correlation 5y	50.1%
CAGR 5y	11.28%
CAGR/Max DD 3y (Calmar Ratio)	0.23
CAGR/Mean DD 3y (Pain Ratio)	0.51
Sharpe Ratio 12m	1.33
Alpha	-3.17
Beta	1.162
Volatility	38.94%
Current Volume	1512.9k
Average Volume 20d	1652.6k
Stop Loss	66.1 (-3.2%)
Signal	1.44

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (557.3m TTM) > 0 and > 6% of Revenue (6% = 70.7m TTM)

FCFTA 0.26 (>2.0%) and ΔFCFTA 5.59pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 83.86% (prev 97.84%; Δ -13.98pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.27 (>3.0%) and CFO 547.8m <= Net Income 557.3m (YES >=105%, WARN >=100%)

Net Debt (1.45b) to EBITDA (791.8m) ratio: 1.83 <= 3.0 (WARN <= 3.5)

Current Ratio 8.36 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (124.2m) change vs 12m ago -3.92% (target <= -2.0% for YES)

Gross Margin 84.20% (prev 75.89%; Δ 8.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 58.59% (prev 44.34%; Δ 14.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 39.49 (EBITDA TTM 791.8m / Interest Expense TTM 18.0m) >= 6 (WARN >= 3)

Altman Z'' 6.31

(A) 0.48 = (Total Current Assets 1.12b - Total Current Liabilities 134.3m) / Total Assets 2.05b

(B) 0.18 = Retained Earnings (Balance) 361.0m / Total Assets 2.05b

(D) 0.19 = Book Value of Equity 332.7m / Total Liabilities 1.72b

Total Rating: 6.31 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 86.32

1. Piotroski 7.0pt = 2.0

2. FCF Yield 6.30% = 3.15

3. FCF Margin 45.87% = 7.50

4. Debt/Equity 4.54 = -2.39

5. Debt/Ebitda 1.83 = 0.34

6. ROIC - WACC (= 21.25)% = 12.50

7. RoE 136.6% = 2.50

8. Rev. Trend 84.12% = 6.31

9. EPS Trend 88.41% = 4.42

What is the price of HALO shares?

As of November 06, 2025, the stock is trading at USD 68.30 with a total of 1,512,923 shares traded.
Over the past week, the price has changed by +4.66%, over one month by +1.99%, over three months by +12.32% and over the past year by +16.31%.

Is Halozyme Therapeutics a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Halozyme Therapeutics (NASDAQ:HALO) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 86.32 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HALO is around 65.27 USD . This means that HALO is currently overvalued and has a potential downside of -4.44%.

Is HALO a buy, sell or hold?

Halozyme Therapeutics has received a consensus analysts rating of 3.63. Therefor, it is recommend to hold HALO.

Strong Buy: 2
Buy: 2
Hold: 3
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the HALO price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	75.7	10.8%
Analysts Target Price	75.7	10.8%
ValueRay Target Price	72.9	6.7%

HALO Fundamental Data Overview November 02, 2025

Market Cap USD = 7.63b (7.63b USD * 1.0 USD.USD)
P/E Trailing = 14.9176
P/E Forward = 8.19
P/S = 6.4692
P/B = 25.2001
P/EG = -2.5
Beta = 1.162
Revenue TTM = 1.18b USD
EBIT TTM = 710.1m USD
EBITDA TTM = 791.8m USD
Long Term Debt = 1.51b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 1.51b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.45b USD (from netDebt column, last quarter)
Enterprise Value = 8.59b USD (7.63b + Debt 1.51b - CCE 548.2m)
Interest Coverage Ratio = 39.49 (Ebit TTM 710.1m / Interest Expense TTM 18.0m)
FCF Yield = 6.30% (FCF TTM 540.7m / Enterprise Value 8.59b)
FCF Margin = 45.87% (FCF TTM 540.7m / Revenue TTM 1.18b)
Net Margin = 47.28% (Net Income TTM 557.3m / Revenue TTM 1.18b)
Gross Margin = 84.20% ((Revenue TTM 1.18b - Cost of Revenue TTM 186.2m) / Revenue TTM)
Gross Margin QoQ = 85.77% (prev 81.73%)
Tobins Q-Ratio = 4.18 (Enterprise Value 8.59b / Total Assets 2.05b)
Interest Expense / Debt = 0.29% (Interest Expense 4.39m / Debt 1.51b)
Taxrate = 19.41% (39.8m / 204.9m)
NOPAT = 572.3m (EBIT 710.1m * (1 - 19.41%))
Current Ratio = 8.36 (Total Current Assets 1.12b / Total Current Liabilities 134.3m)
Debt / Equity = 4.54 (Debt 1.51b / totalStockholderEquity, last quarter 332.7m)
Debt / EBITDA = 1.83 (Net Debt 1.45b / EBITDA 791.8m)
Debt / FCF = 2.68 (Net Debt 1.45b / FCF TTM 540.7m)
Total Stockholder Equity = 407.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 27.13% (Net Income 557.3m / Total Assets 2.05b)
RoE = 136.6% (Net Income TTM 557.3m / Total Stockholder Equity 407.9m)
RoCE = 37.04% (EBIT 710.1m / Capital Employed (Equity 407.9m + L.T.Debt 1.51b))
RoIC = 29.89% (NOPAT 572.3m / Invested Capital 1.91b)
WACC = 8.64% (E(7.63b)/V(9.13b) * Re(10.30%) + D(1.51b)/V(9.13b) * Rd(0.29%) * (1-Tc(0.19)))
Discount Rate = 10.30% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.66%
[DCF Debug] Terminal Value 73.97% ; FCFE base≈487.7m ; Y1≈584.9m ; Y5≈934.8m
Fair Price DCF = 93.39 (DCF Value 10.92b / Shares Outstanding 117.0m; 5y FCF grow 21.26% → 3.0% )
EPS Correlation: 88.41 | EPS CAGR: 30.54% | SUE: 3.44 | # QB: 6
Revenue Correlation: 84.12 | Revenue CAGR: 17.51% | SUE: 2.27 | # QB: 2

Additional Sources for HALO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle